



Serial Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Esophageal Adenocarcinoma Patients Following Resection

Adenocarcinoma of the esophagus is rapidly increasing in incidence.¹ Esophageal adenocarcinoma (EAC) is frequently advanced at presentation, and even when treated with multimodality therapy, is cured in less than 50% of operated-on patients.^{2,3}

Circulating tumor DNA (ctDNA) has shown promise as a prognostic tool in multiple cancers and is a predictive biomarker for treatment in non-small cell lung cancer.^{4,5} We recently confirmed the prognostic value of ctDNA using a non-EAC-specific panel in a large population of resected EAC.⁶ In brief, patients who were ctDNA-positive after resection had worse survival than ctDNA-negative patients (hazard ratio, 5.55; 95% confidence interval, 2.42-12.71; $P = .0003$).⁶ However, the sensitivity of a tumor-naïve panel for detecting recurrence was only 35%, implying many patients who recur are not detected.⁶ In this study, we tested whether a personalized, tumor-informed assay would demonstrate superior sensitivity for detecting minimal residual disease (MRD) in patients with resected EAC.

In this retrospective study, blood samples were collected from 20 patients with EAC who underwent surgery or endoscopic mucosal resection (EMR). Blood samples were collected before and after surgical treatment. This study was conducted in accordance with the International Conference on Harmonization-Good Clinical Practice Guidelines and approved by the United Kingdom National Ethics Framework (LREC, 10-H0305-1). All patients provided written informed consent.

We identified tumor-specific variants using whole-genome sequencing data from our International Cancer Genome Consortium project, mean coverage: 73x (tumor) and 37x (blood reference).⁷ We then used 16 of these patient-specific somatic single-nucleotide variants to design individualized multiplex polymerase chain reaction-based primers for next-generation sequencing, used to identify ctDNA in patient plasma.

For survival analysis, only patients who underwent surgery were included. Patients who underwent EMR were expected to be cured and were excluded. Survival estimates were calculated using the Kaplan-Meier method, and survival plots were created using “survminer” R 0.4.4 software (R Foundation for Statistical Computing). Survival differences were evaluated by univariate Cox regression analysis using the “survival” R 2.44-1.1 package. P values were determined using the log-likelihood test.

At least 1 sample was taken from all patients before and after tumor removal (Figure 1A).

Patient characteristics were consistent with those expected in patients with EAC (median age, 62 years; 85% men) (Supplementary Table 1). Most (17 of 20 [85%]) were treated with perioperative chemotherapy.

Patients with deeper penetration of the gastroesophageal mucosa were more likely to have ctDNA identified

preoperatively (9 of 12 [75%] cT3 vs 2 of 5 [40%] T2); however, groups were similar with respect to cN, yN, and lymphovascular invasion (Supplementary Figure 1A). All patients that recurred were ctDNA-positive at baseline (100% sensitivity, $P < .0001$) (Supplementary Figure 1B). Patients who were ctDNA-positive before surgery had significantly poorer disease-free survival (DFS) ($P = .042$), with a median DFS of 32.0 months vs 63.0 months in ctDNA-negative preoperative patients. There was also a trend towards poorer cancer-specific survival (Supplementary Figure 1C and D). None of the presurgical ctDNA-negative patients relapsed after surgery (Supplementary Figure 1C). Of the 11 presurgical ctDNA-positive patients, 5 (45%) relapsed after surgery.

Four patients were ctDNA-positive after surgery and relapsed, 1 patient, who was ctDNA-negative, developed recurrence 2.6 years after the last ctDNA testing, leading to a sensitivity of 80% (4 of 5) and specificity of 100% (12 of 12). Median DFS was 14.2 months vs 51.2 months in ctDNA-positive vs ctDNA-negative in postoperative patients, respectively (Figure 1B), and median cancer-specific survival was 18.0 months vs 53.4 months (Figure 1C). ctDNA-positivity at this time point was associated with inferior DFS ($P < .0001$). When patients who did not have a plasma sample within 1 year of relapse were excluded, sensitivity and specificity were 100%. The median ctDNA variant allele fraction detected in positive samples after surgery was 0.01% (range, 0.001%-15.9%). Response to neoadjuvant chemotherapy was reflected in the ctDNA fraction; a patient with a complete response to neoadjuvant chemotherapy was ctDNA-negative after treatment (Figure 1D). In contrast residual disease was detected in patients who had a poor response to neoadjuvant chemotherapy, including a patient where the ctDNA fraction increased during treatment (Figure 1E).

To our knowledge, this study is the first to investigate the use of a tumor-informed ctDNA assay to detect MRD in resected EAC. We demonstrate excellent sensitivity and specificity of personalized ctDNA assays for the detection of ctDNA in patients after surgical resection. Recurrent disease developed in all patients with ctDNA detected postoperatively. This sensitive ctDNA assay provided a median lead time of almost 1 year before clinical or radiologic recurrence.


One patient who was ctDNA-negative 6 months postoperatively developed a late potentially low ctDNA shedding peritoneal recurrence >4 years after surgery; the last ctDNA sample available for this patient was >2 years before

Most current article


© 2021 by the AGA Institute. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).
0016-5085

<https://doi.org/10.1053/j.gastro.2021.07.011>


A




B



C



D



E




Figure 1. (A) Sample timelines of the 20 patients (P) in the cohort. (B) Disease-free survival (DFS) in patients according to circulating tumor (ct)DNA status post-surgery. (C) Cancer-related survival in patients according to postsurgical ctDNA status. (D) Patient who had a good response to chemotherapy, tumor regression grade 1, lead time on patient, 278 days. (E) Patient remained ctDNA-positive throughout treatment, and lead time was >500 days. CT, computed tomography; EMR, endoscopic mucosal resection; OAC, oesophageal adenocarcinoma; PET, positron emission tomography; 5'FU, 5'-fluorouracil.

relapse. This implies both temporal and anatomic reasons for the lack of a ctDNA-positive result predicting relapse for this patient. Interestingly, ctDNA preoperatively was modestly prognostic, and this was also associated with tumor stage. Crucially, patients who were ctDNA-positive preoperatively and became ctDNA-negative after surgery had a good prognosis, indicating that ctDNA is a valuable dynamic biomarker.

In colorectal cancer, individualized ctDNA assessment after surgery can be considered a standard of care while the predictive value of such assays is under investigation in large, randomised trials.⁸ In resected EAC, in part due to surgical morbidity, fewer than half of the patients currently undergo the adjuvant component of perioperative chemotherapy.³ The benefit of reserving adjuvant chemotherapy for patients most likely to recur or switching to an alternative regimen should be evaluated prospectively. In addition, personalized ctDNA detection could also provide insight on the most suitable treatment option for the patient based on their ctDNA levels after neoadjuvant chemotherapy. Our study also suggests that longitudinal monitoring of ctDNA rather than a sample at a single time point could be valuable, because a minority of patients may have late recurrences.

This study is limited by modest sample size; however, given the robust, individualized methodology of our approach, we believe that these results are likely to be generalizable.

In summary, this study demonstrates that personalized ctDNA assays provide a tool with potential clinical application to predict relapse in patients with resected EAC. The next step will be to design prospective clinical trials that risk stratify adjuvant therapy based on MRD.

Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Gastroenterology* at www.gastrojournal.org, and at <https://doi.org/10.1053/j.gastro.2021.07.011>.

EMMA OCOCKS

Medical Research Council Cancer Unit
Hutchison/Medical Research Council Research Centre
University of Cambridge
Cambridge, United Kingdom

SHRUTI SHARMA

Research and Development Department
Natera, Incorporated
San Carlos, California

ALVIN WEI TIAN NG

Cancer Research UK Cambridge Institute
University of Cambridge
Cambridge, United Kingdom

OCCAMS CONSORTIUM

Medical Research Council Cancer Unit
Hutchison/Medical Research Council Research Centre
University of Cambridge
Cambridge, United Kingdom

ALEXEY ALESHIN

Medical Affairs, Oncology
Natera, Incorporated
San Carlos, California

REBECCA C. FITZGERALD

Medical Research Council Cancer Unit
Hutchison/Medical Research Council Research Centre
University of Cambridge
Cambridge, United Kingdom

ELIZABETH SMYTH

Medical Oncology
Cambridge University Hospitals
National Health Service Foundation Trust
Addenbrooke's Hospital
Cambridge, United Kingdom

References

1. Edgren G, et al. *Gut* 2013;62:1406–1414.
2. Cancer Research UK. <https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence>.
3. Al-Batran SE, et al. *Lancet* 2019;393:1948–1957.
4. Tie J, et al. *Sci Transl Med* 2016;8:346ra92.
5. Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, et al. *Nature* 2017; 545:446–451.
6. Ococks E, Frankell AM, Soler NM, et al. *Ann Oncol* 2021;32:522–532.
7. Frankell AM, et al. *Nat Genet* 2019;51:506–516.
8. Tie J, Cohen JD, et al. *JAMA Oncol* 2019;5:1710–1717.

Author names in bold designate shared co-first authorship.

Received May 10, 2021. Accepted July 14, 2021.

Correspondence

Address correspondence to: Rebecca C. Fitzgerald, MD, Medical Research Council Cancer Unit, Hutchison/Medical Research Council Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge CB2 0XZ, United Kingdom. e-mail: rcf29@cam.ac.uk.

Data Transparency Statement

Whole-genome sequencing is available via the European Genome-phenome Archive (EGAD00001007659). Code is available on request. Clinical data and circulating tumor DNA results (mean tumor molecules/mL of plasma) at each time point can be made available upon request.

Conflicts of interest

These authors disclose the following: Rebecca C. Fitzgerald received an educational grant from Roche, is a share-holder and consultant for Cytel Ltd, and has received grant support from Medtronic. Emma Ococks has received honoraria and/or travel and accommodation expenses from Roche.

Elizabeth Smyth has received an honorarium from Roche, Astellas, AstraZeneca, BMS, Merck, Celgene, Five Prime, Gritstone Oncology, and Servier. Shruti Sharma and Alexey Aleshin are employees of Natera, Inc, with stock/options to own stock in the company. Alvin Wei Tian Ng discloses no conflicts.

Acknowledgments

The authors thank Ginny Devonshire for data management and storage.

CRedit Authorship Contributions

Emma Ococks, MSc (Formal analysis: Lead; Visualization: Lead; Writing – original draft: Equal). Shruti Sharma, PhD (Formal analysis: Equal; Visualization: Supporting; support with clinical interpretation: Equal). Alvin Wei Tian Ng, PhD (Data curation: Lead). Oesophageal Cancer Clinical and Molecular Stratification Consortium, UK (Consortium: Supporting). Alexey Aleshin, MD, MBA (support with clinical interpretation: Supporting). Rebecca C. Fitzgerald, MD (Funding acquisition: Lead; Supervision: Lead; Writing – original draft: Equal). Elizabeth Smyth, MD (Supervision: Equal; Writing – original draft: Equal).

Funding


Oesophageal Cancer Clinical and Molecular Stratification and whole genome sequencing of primary tumor samples was funded by a Cancer Research UK Program Grant (RG66287). The laboratory of RCF is funded by a Medical Research Council Core Program Grant. Plasma sample library preparation and sequencing cost was covered by Natera.

Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium

Rebecca C. Fitzgerald,¹ Paul A.W. Edwards,^{1,2} Nicola Grehan,¹ Barbara Nutzinger,¹ Elwira Fidziukiewicz,¹ Aisling M. Redmond,¹ Alex Northrop,¹ Sujath Abbas,¹ Elizabeth C. Smyth,³ Maria O'Donovan,^{1,4} Ahmad Miremadi,^{1,4} Shalini Malhotra,^{1,4} Monika Tripathi,^{1,4} Amber Grantham,¹ Calvin Cheah,¹ Hannah Coles,¹ Connor Flint,¹ Matthew Eldridge,² Maria Secier,² Ginny Devonshire,² Sriganesh Jammula,² Jim Davies,⁵ Charles Crichton,⁵ Nick Carroll,³ Richard H. Hardwick,³ Peter Safranek,³ Andrew Hindmarsh,³ Vijayendran Sujendran,³ Stephen J. Hayes,^{6,7} Yeng Ang,^{6,8,9} Andrew Sharrocks,⁹ Shaun R. Preston,¹⁰ Izhar Bagwan,¹⁰ Vicki Save,¹¹ Richard J.E. Skipworth,¹¹ Ted R. Hupp,¹² J. Robert O'Neill,^{3,11,12} Olga Tucker,^{13,14} Andrew Beggs,^{13,15} Philippe Taniere,¹³ Sonia Puig,¹³ Gianmarco Contino,¹³ Timothy J. Underwood,^{16,17} Robert C. Walker,^{16,17} Ben L. Grace,¹⁶ Jesper Lagergren,^{18,19} James Gossage,^{18,20} Andrew Davies,^{18,20} Fujun Chang,^{18,20} Ula Mahadeva,¹⁸ Vicky Goh,²⁰ Francesca D. Ciccarelli,²⁰ Grant Sanders,²¹ Richard Berrisford,²¹ David Chan,²¹ Ed

Cheong,²² Bhaskar Kumar,²² L. Sreedharan,²² Simon L. Parsons,²³ Irshad Soomro,²³ Philip Kaye,²³ John Saunders,^{6,23} Laurence Lovat,²⁴ Rehan Haidry,²⁴ Michael Scott,²⁵ Sharmila Sothi,²⁶ Suzy Lishman,²⁷ George B. Hanna,²⁸ Christopher J. Peters,²⁸ Krishna Moorthy,²⁸ Anna Grabowska,²⁹ Richard Turkington,³⁰ Damian McManus,³⁰ Helen Coleman,³⁰ and Russell D. Petty.³¹

¹Medical Research Council Cancer Unit, Hutchison/Medical Research Council Research Centre, University of Cambridge, Cambridge, United Kingdom; ²Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom; ³Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, United Kingdom; ⁴Department of Histopathology, Addenbrooke's Hospital, Cambridge, United Kingdom; ⁵Department of Computer Science, University of Oxford, Oxford, United Kingdom; ⁶Salford Royal National Health Service Foundation Trust, Salford, United Kingdom; ⁷Faculty of Medical and Human Sciences, University of Manchester, United Kingdom; ⁸Wigan and Leigh National Health Service Foundation Trust, Wigan, Manchester, United Kingdom; ⁹GI Science Centre, University of Manchester, United Kingdom; ¹⁰Royal Surrey County Hospital National Health Service Foundation Trust, Guildford, United Kingdom; ¹¹Edinburgh Royal Infirmary, Edinburgh, United Kingdom; ¹²Edinburgh University, Edinburgh, United Kingdom; ¹³University Hospitals Birmingham National Health Service Foundation Trust, Birmingham, United Kingdom; ¹⁴Heart of England National Health Service Foundation Trust, Birmingham, United Kingdom; ¹⁵Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom; ¹⁶University Hospital Southampton National Health Service Foundation Trust, Southampton, United Kingdom; ¹⁷Cancer Sciences Division, University of Southampton, Southampton, United Kingdom; ¹⁸Guy's and St Thomas's National Health Service Foundation Trust, London, United Kingdom; ¹⁹Karolinska Institute, Stockholm, Sweden; ²⁰King's College London, London, United Kingdom; ²¹Plymouth Hospitals National Health Service Trust, Plymouth, United Kingdom; ²²Norfolk and Norwich University Hospital National Health Service Foundation Trust, Norwich, United Kingdom; ²³Nottingham University Hospitals National Health Service Trust, Nottingham, United Kingdom; ²⁴University College London, London, United Kingdom; ²⁵Wythenshawe Hospital, Manchester, United Kingdom; ²⁶University Hospitals Coventry and Warwickshire National Health Service Trust, Coventry, United Kingdom; ²⁷Peterborough Hospitals National Health Service Trust, Peterborough City Hospital, Peterborough, United Kingdom; ²⁸Department of Surgery and Cancer, Imperial College, London, United Kingdom; ²⁹Queen's Medical Centre, University of Nottingham, Nottingham, United Kingdom; ³⁰Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, United Kingdom; ³¹Tayside Cancer Centre, Ninewells Hospital and Medical School, Dundee, United Kingdom.



Supplementary Figure 1. (A) Presurgical detection of circulating tumor (ct)DNA across different stages. (B) Presurgical detection of ctDNA according to relapse status. (C) Disease-free survival (DFS) in patients according to ctDNA status at baseline. (D) Cancer-related survival in patients according to baseline ctDNA status.

Supplementary Table 1. Clinical Demographics of Cohort

Variable	No. or Median	
	(N = 20)	% or Range
Sex		
Male	17	85
Female	3	15
Age, y	62.8	48.9–80.8
T stage		
T1a	2	10
T1	1	5
T2	5	25
T3	12	60
N stage		
N0	9	45
N1	6	30
N2	2	10
N3	1	5
Nx	2	10
Treatment		
Surgery	17	85
Endoscopic mucosal resection	3	15
Chemotherapy		
Yes	17	85
No	3	15
Siewert's classification		
1	12	60
2	5	25
3	3	15